OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
July 11, 2023
Webinar Date/Time: Tue, Aug 8, 2023 11:00 AM EDT
July 07, 2023
Thermo Fisher Scientific’s new tumoroid culture medium kit is designed to help cancer researchers better model the disease.
Eurofins Genomics Blue Heron’s novel mRNA synthesis service is designed for customizable applications.
July 06, 2023
Chime Biologics, Leads Biolabs, and BeiGene have formed a three-way collaboration to advance the development and global manufacturing of Leads Biolabs’ lead mAb candidate, LBL-007.
July 03, 2023
FDA’s new guidance on in-vitro permeation test studies published in October 2022 gives technical and statistical requirements for conducting these tests to compare topical generic drugs with their reference products.
Sample dilution, sensitivity, excipient interference, and containment are key issues that must be addressed.
June 23, 2023
Aenova has opened a new building for the production of highly potent APIs in Germany.
Sandbox AQ’s molecular simulation division is collaborating with companies like AstraZeneca and Sanofi to develop novel treatments for various disorders.
June 14, 2023
The new excipients manufacturing facility is expected to be completed in 2025.
June 09, 2023
Webinar Date/Time: Tue, Jul 25, 2023 9:00 AM EDT